Literature DB >> 9267730

Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis.

B Kunz1, A P Oranje, L Labrèze, J F Stalder, J Ring, A Taïeb.   

Abstract

BACKGROUND: We have previously reported how the SCORAD index was designed. This cumulative index combines objective (extent and intensity of lesions) and subjective (daytime pruritus and sleep loss) criteria. AIMS: To study interobserver variability in scoring for objective SCORAD criteria and to optimize the scoring guidelines.
MATERIAL AND METHODS: Three scoring sessions were organized in 1993-1994 in Hamburg, Bordeaux and Rotterdam totalizing 19 patients (14 children and 5 adults) and 23 physicians, among whom 12 participated in at least 2 scoring sessions; 169 evaluation sheets have been processed using the SCORAD File Marker Pro software. At each session, total body photographs and close-up views were taken of each patient, and this material was reviewed at the final evaluation.
RESULTS: The extent of lesions according to the rule of nines showed interobserver variability mostly for patients with lesions of moderate intensity involving 20-60% of body surface. Intensity items were scored with more consistency overall, but variations subsided especially for oozing/crusts and lichenifications. Low and high scorer profiles and the benefit of training were noted.
CONCLUSIONS: This study has allowed to optimize clinical scoring using the SCORAD system. A proposal has been made to grade the severity of atopic dermatitis according to objective criteria in three groups for inclusion in clinical trials. The SCORAD index remains the major criterion for follow-up in trials.

Entities:  

Mesh:

Year:  1997        PMID: 9267730     DOI: 10.1159/000245677

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  164 in total

1.  Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands.

Authors:  I Lenoir-Wijnkoop; W M C van Aalderen; G Boehm; D Klaassen; A B Sprikkelman; M J C Nuijten
Journal:  Eur J Health Econ       Date:  2010-12-17

2.  [Measurement of disease severity in dermatology].

Authors:  S Deckert; C Apfelbacher; J Schmitt
Journal:  Hautarzt       Date:  2015-09       Impact factor: 0.751

3.  A randomised study of "wet wraps" versus conventional treatment for atopic eczema.

Authors:  D Hindley; G Galloway; J Murray; L Gardener
Journal:  Arch Dis Child       Date:  2005-11-24       Impact factor: 3.791

4.  Association of staphylococcal superantigen-specific immunoglobulin e with mild and moderate atopic dermatitis.

Authors:  Peck Y Ong; Mona Patel; Ronald M Ferdman; Theresa Dunaway; Joseph A Church
Journal:  J Pediatr       Date:  2008-07-14       Impact factor: 4.406

5.  Long-term safety of replication-defective smallpox vaccine (MVA-BN) in atopic eczema and allergic rhinitis.

Authors:  U Darsow; M Sbornik; S Rombold; K Katzer; F von Sonnenburg; H Behrendt; J Ring
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-06-29       Impact factor: 6.166

6.  Omalizumab for patients with severe and therapy-refractory atopic eczema?

Authors:  Christian Andres; Benedetta Belloni; Martin Mempel; Johannes Ring
Journal:  Curr Allergy Asthma Rep       Date:  2008-05       Impact factor: 4.806

7.  A mixture of prebiotic oligosaccharides reduces the incidence of atopic dermatitis during the first six months of age.

Authors:  G Moro; S Arslanoglu; B Stahl; J Jelinek; U Wahn; G Boehm
Journal:  Arch Dis Child       Date:  2006-07-27       Impact factor: 3.791

8.  First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis.

Authors:  Ian A Myles; Noah J Earland; Erik D Anderson; Ian N Moore; Mark D Kieh; Kelli W Williams; Arhum Saleem; Natalia M Fontecilla; Pamela A Welch; Dirk A Darnell; Lisa A Barnhart; Ashleigh A Sun; Gulbu Uzel; Sandip K Datta
Journal:  JCI Insight       Date:  2018-05-03

9.  Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt.

Authors:  Mohamed A El-Khalawany; Hatem Hassan; Dalia Shaaban; Noha Ghonaim; Bayoumi Eassa
Journal:  Eur J Pediatr       Date:  2012-11-16       Impact factor: 3.183

10.  Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin.

Authors:  Patrick A M Jansen; Diana Rodijk-Olthuis; Edward J Hollox; Marijke Kamsteeg; Geuranne S Tjabringa; Gys J de Jongh; Ivonne M J J van Vlijmen-Willems; Judith G M Bergboer; Michelle M van Rossum; Elke M G J de Jong; Martin den Heijer; Andrea W M Evers; Mieke Bergers; John A L Armour; Patrick L J M Zeeuwen; Joost Schalkwijk
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.